Literature DB >> 34950304

Prevalence and Impact of Atrial Fibrillation in a Cohort of Patients with Hypertrophic Cardiomyopathy in Ireland.

McClelland S1, O'Connor Sa2, Donohue S1, Lavelle L1, McErlean A3, Dodd Jd1, Meaney J2, McCreery Cj1, McDonald K1, Quinn M1, Erwin Je1, Quigley Pj1, Maurer B4, Keane D1.   

Abstract

AIMS: Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), and is associated with deterioration in clinical status and outcome. To date, no data have been published pertaining to AF in an Irish HCM population. METHODS AND
RESULTS: 159 patients with HCM attending St Vincent's University Hospital and Blackrock Clinic, Dublin, were identified. Detailed review of medical notes, Holter monitor, echocardiogram, cardiac MRI (CMR) and implantable cardioverter-defibrillator (ICD) records was performed.Prevalence of AF was 38.4%. HCM patients with AF (HCM-AF) were older (60.6±14.8 v 54.9±17.3 years, P=0.016) and more symptomatic (NYHA II: 29.7% v 16.9%, NYHA III: 4.3% v 1.2%) than HCM patients without AF. History of stroke was recorded in 16.4% of HCM-AF patients, compared with 1% in those without AF.HCM-AF patients had lower left ventricular ejection fraction (echo: 59.5±11.8v68±8, P<0.001; CMR: 62.3%v70.5%, P<0.01) and higher left atrial diameter (echo: 49.8±9.5v40.9±7.4, p<0.001; CMR 62.3±11.3v70.4±9, p<0.001), compared with those without AF. Myocardial fibrosis was detected on CMR in 74% of HCM-AF patients and 62% of those without AF.34% of patients had an ICD in situ, of whom 61% had AF. 24% of these HCM-AF patients received inappropriate shocks, all triggered by AF.
CONCLUSION: AF is common in the Irish HCM population. It is associated with increased risk of stroke, deterioration in symptom status and is a common trigger for inappropriate ICD discharge. We have shown, in-keeping with previous studies, that AF is associated with reduced EF, increased LA diameter and mitral regurgitation in this HCM population.

Entities:  

Keywords:  Atrial fibrillation; Cardiac MRI; Hypertrophic Cardiomyopathy; Left Atrium

Year:  2020        PMID: 34950304      PMCID: PMC8691344          DOI: 10.4022/jafib.2337

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  27 in total

1.  Does the progression of myocardial fibrosis lead to atrial fibrillation in patients with hypertrophic cardiomyopathy?

Authors:  K Yamaji; S Fujimoto; C Yutani; Y Ikeda; R Mizuno; T Hashimoto; S Nakamura
Journal:  Cardiovasc Pathol       Date:  2001 Nov-Dec       Impact factor: 2.185

2.  The Italian Registry for hypertrophic cardiomyopathy: a nationwide survey.

Authors:  Franco Cecchi; Iacopo Olivotto; Sandro Betocchi; Claudio Rapezzi; Maria Rosa Conte; Gianfranco Sinagra; Elisabetta Zachara; Antonello Gavazzi; Roberto Rordorf; Gianfranco Carnemolla; Maurizio Porcu; Stefano Nistri; Paolo Gruppillo; Simona Giampaoli
Journal:  Am Heart J       Date:  2005-11       Impact factor: 4.749

3.  A survey of the causes of sudden cardiac death in the under 35-year-age group.

Authors:  F Quigley; M Greene; D O'Connor; F Kelly
Journal:  Ir Med J       Date:  2005-09

4.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  Rory O'Hanlon; Agata Grasso; Michael Roughton; James C Moon; Susan Clark; Ricardo Wage; Jessica Webb; Meghana Kulkarni; Dana Dawson; Leena Sulaibeekh; Badri Chandrasekaran; Chiara Bucciarelli-Ducci; Ferdinando Pasquale; Martin R Cowie; William J McKenna; Mary N Sheppard; Perry M Elliott; Dudley J Pennell; Sanjay K Prasad
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

5.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population.

Authors:  B J Maron; I Olivotto; P Spirito; S A Casey; P Bellone; T E Gohman; K J Graham; D A Burton; F Cecchi
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

6.  Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study.

Authors:  Toru Kubo; Hiroaki Kitaoka; Makoto Okawa; Takayoshi Hirota; Kayo Hayato; Naohito Yamasaki; Yoshihisa Matsumura; Toshikazu Yabe; Jun Takata; Yoshinori L Doi
Journal:  Circ J       Date:  2009-07-09       Impact factor: 2.993

7.  Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with non-invasive P-wave analysis.

Authors:  Chrysafios Girasis; Vassilios Vassilikos; Georgios K Efthimiadis; Stella-Lida Papadopoulou; Georgios Dakos; Emmanuela G Dalamaga; Ioanna Chouvarda; Georgios Giannakoulas; Vassilios Kamperidis; Stylianos Paraskevaidis; Nicos Maglaveras; Haralambos I Karvounis; Georgios E Parcharidis; Ioannis H Styliadis
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-08-17       Impact factor: 6.875

8.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Authors:  Perry M Elliott; Aris Anastasakis; Michael A Borger; Martin Borggrefe; Franco Cecchi; Philippe Charron; Albert Alain Hagege; Antoine Lafont; Giuseppe Limongelli; Heiko Mahrholdt; William J McKenna; Jens Mogensen; Petros Nihoyannopoulos; Stefano Nistri; Petronella G Pieper; Burkert Pieske; Claudio Rapezzi; Frans H Rutten; Christoph Tillmanns; Hugh Watkins
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

9.  Causes of death and mortality in hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden.

Authors:  Peter Magnusson; Fredrik Gadler; Per Liv; Stellan Mörner
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2016-07       Impact factor: 2.160

10.  Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study.

Authors:  S Pujadas; R Vidal-Perez; A Hidalgo; R Leta; F Carreras; A Barros; A Bayes-Genis; M T Subirana; Guillem Pons-Llado
Journal:  Eur J Radiol       Date:  2010-01-15       Impact factor: 3.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.